An observational study in Diabete Type 2, sponsored by Tameside General Hospital. Completed at 1 site in United Kingdom. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-09-09.
Sponsored by Tameside General Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom — 57 open to participants now, 73 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · United Kingdom.
Among the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, this one is the 12th largest by enrollment of the 77 observational ones that give a count, is one of 22 that started in 2022, is one of 77 observational ones, and was the 462nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →57 of the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Ascletis Pharma (China) Co., Limited · Sites in United Kingdom, United States, Czechia and 3 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in United Kingdom, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 30 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
572 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 59 · Phase 3 187 · Phase 4 58
First in 1997; this study’s year is marked. 22 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,050 is above the median of 300 across 1,744 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 207 across the 495 interventional studies, 593 across the 77 observational. Of the 462 that completed or were terminated, 194 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 572 have an industry lead sponsor. The 10 most frequent:
Tameside General Hospital is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Tameside General Hospital has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
16 of the studies in Diabetes Mellitus, Type 2 with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT06652763University of LeicesterManganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction | 2026-11 |
Add all 16 to your calendar (.ics) → With an account.
Among the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
People with type 2 diabetes are two-and-a-half times more likely to experience heart failure and twice more likely to have a heart attack compared to people without diabetes. People coming to hospital often have unknown hyperglycaemia. It is thought that three quarters of people admitted to the Coronary care unit with a myocardial infarction have hyperglycaemia and over a third of whom are undiagnosed with diabetes and over 40% with impaired glucose tolerance (IGT). All of these patients are at greater risk of poor outcomes in the presence of uncontrolled hyperglycaemia.
Patients presenting to A\&E have routine bloods taken for condition which are they are being investigated and treated for. Therefore the aim of the study is to identify the prevalence of undiagnosed diabetes (HbA1c >48mmol/mol) or impaired glucose tolerance/pre-diabetes (HbA1c >39mmol/mol) in patients attending the accident and emergency department or acute medical unit and to see if this is a good screening measure for diagnosis of diabetes. This project will help identify those undiagnosed with glucose intolerance (T2D and IGT) and instigate appropriate treatment and improve outcomes for this group of patients. This will in the long term reduce the burden to the NHS. This project will help in the development of guidance for diagnosis of T2D in an acute setting and treatment for hospital admission and continued care.
This project will include 10,000 consecutive patients over the age of 30 years attending the A\&E or AMU departments of Tameside and Glossop Integrated Care NHS FT. All patients will be screened for glucose intolerance with a blood test in which patients' blood would be taken anyway for clinical reasons and the laboratory will perform an HbA1c investigation on the sample collected.
Study aims
Primary research question What is the prevalence of glucose intolerance (diabetes and IGT) in patients presenting to an acute medical emergency department?
Objectives
The aim of the project is to see whether this is a simple method of identifying the many patients who have undiagnosed glucose intolerance and ensuring those who are identified are commenced on the right treatment path for them to reduce both individual risk and burden to the NHS.
Patients presenting to A\&E have routine bloods taken for condition which are they are being investigated and treated for. Therefore the aim is to identify the prevalence of undiagnosed diabetes (HbA1c >48mmol/mol) or impaired glucose tolerance/pre-diabetes (HbA1c >39mmol/mol) in patients attending the accident and emergency department or acute medical unit and to see if this is a good screening measure for diagnosis of diabetes. This project will help identify those undiagnosed with glucose intolerance (T2D and IGT) and instigate appropriate treatment and improve outcomes for this group of patients. This will in the long term reduce the burden to the NHS. This project will help in the development of guidance for diagnosis of T2D in an acute setting and treatment for hospital admission and continued care.
This project will include 10,000 consecutive patients over the age of 30 years attending the A\&E or AMU departments of Tameside and Glossop Integrated Care NHS FT. All patients will be screened for glucose intolerance with a blood test in which patients' blood would be taken anyway for clinical reasons and we will perform an HbA1c investigation on the sample collected.
In addition to measuring HbA1c the investigators will look for other risk factors, such as socio economic status, obesity, ethnicity, weekly exercise patterns and other metabolic factors (e.g. lipids).
All results will be forwarded to the GP with advice on management if HbA1c is raised and to follow-up the patient.
This will be the largest UK project to include patients presenting to A\&E and assessed for underlying glucose intolerance. The project will run for 12 months.
Study design
Due to the observational nature of this study, no blinding is required to the investigators as the primary question is laboratory diagnosis and not treatment received
This will be an observational cohort study of patients hospitalised at Tameside General Hospital,
Patient demographic details will be extracted from their clinical notes and electronic patient records, then placed on an anonymised database for analysis. Data will be analysed to determine findings, including diagnosis of T2D/IGT, reason for admission, presence of diabetic complications (microvascular / macrovascular). Projected recruitment is minimum of 10,000 patients to be opportunistically recruited from A\&E and AMU and acute medical wards of TGH.
Study groups
Patients will be opportunistically recruited from in-patient admissions with a medical illness and presenting either to the A\&E, AMU or acute medical wards.
Inclusion criteria:
Exclusion criteria:
Data will be collected for patients based on whether they have been recorded as having a clinical diagnosis of diabetes or not by history and GP records.
A secure, password-encrypted database will be held on a secure server at the hospital, detailing the patient's identifiable details, as well as an assigned study number. Once patient study demographics have been obtained, these will be held on a separate, anonymised database with only the study number as the identifier.
FINDRISC score will be assessed for all patients.
Data Data to be collected Please see Appendix 1 for the data extraction pro forma A detailed list of data to be extracted is laid out in Tables 1 and 2. Data will be collected by co-investigators/research nurses.
Table 1. Data to be collected at enrolment, if available as part of clinical care
Variable Source Form of data Patient identifiable data Electronic patient record (EPR) String Diagnosis on admission Patient medical records String Co-morbidities Patient medical records Binary i.e. has/does not have condition Weight and height EPR/patient medical records Continuous Diabetes Patient medical records Binary i.e. yes/no for each type Treatment history Patient medical records Binary i.e. received/did not receive Vitamin D level (if measured) EPR/laboratory Continuous - could be converted to binary e.g. replete/deplete Vitamin D treatment Patient medical records Binary i.e. yes/no Ethnicity EPR/patient medical records Categorical Creatinine on admission EPR Continuous Foot examination Patient history / examination Binary i.e. yes/no Cardiovascular disease (see proforma) Patient medical records Binary i.e. yes/no Death EPR/patient medical records Binary i.e. yes/no Discharge EPR/patient medical records Binary i.e. yes/no
Data handling and record keeping Data will be manually extracted from the sources detailed above and stored on a password-encrypted database held on Microsoft Excel software. This will be stored on a secure server with standard NHS encryption and firewalls at Tameside General Hospital. Data will be cross-validated by two independent investigators to ensure validity of data and quality of data entry. Records will be retained for ten years after the study concludes for the purposes of potential secondary analysis, then it will be destroyed. However all personal identifiable data will be destroyed at 5 years. All data collection will adhere to the Data Protection Act 1998 and the Caldicott Principles.
Statistical considerations
Sample size calculations Since this is an observational study sample size calculation is not required.
Analysis All analysis will be carried out by principal investigator. Subgroup analysis will also be carried out, stratified by age group, gender and ethnicity. Approximately 20% of the general population of Tameside and Glossop are Black, Asian and Minority Ethnic (BAME), so it is anticipated that subanalysis will be able to be conducted by ethnicity.
Primary analysis will also include logistic regression of ethnic groups against the above treatment outcome variables, with adjustment for age, gender and diabetes status.
Compliance
Subject compliance Compliance will not be an issue, as all data will be gathered from hospital in-patient admission data.
Withdrawal of subjects As this is an observational study, there is no cause for the investigators to withdraw a subject from the study.
Ethical considerations
Appropriate ethical approvals will be sought through the current Health Research Authority (HRA) approval system. Once an outcome has been established, we will update the protocol with the IRAS number.
As the patient data required will already be available as part of clinical care, there will be no need to obtain informed consent from patients. As patients will already be having blood taken for routine care no extra blood will be necessary.
Personal identifiable data will not leave Tameside and Glossop Integrated Care NHS Foundation Trust and will adhere to the GDPR. Confidential patient information will be processed solely for research, in accordance with the Department of Health and Social care Regulation of the Health Service Control of Patient Information Regulations 2002'. Only anonymised data will be included in the results.
Patients who are diagnosed with diabetes will have their results sent to the GP. Appropriate treatment will be instituted if necessary prior to hospital discharge. Patients will receive a copy of the discharge summary and information about diagnosis, blood results and treatments.
Reporting and dissemination
Results of this study will be published in peer-reviewed scientific journals, aiming for those of high impact factor. All data will be anonymised before publication. In addition, results will also be presented at relevant medical conferences, both nationally and internationally. Furthermore, a plain English summary of results will be provided for the Trust and the NIHR websites. Media engagement will be managed via the Trust press office. The plain English summary and overall findings will also be disseminated via the Trust's social media outlets.
Patients attending the accident and emergency department and acute medical wards of a district general hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Blood will be taken as per requirement for patients being admitted to hospital. A small sample will be sent to the biochemistry department for measurement of HbA1 (by HPLC method). All patients who are diagnosed with diabetes (or known to have diabetes) will have a foot examination and retinal and renal screening and cardiovascular assessment for diabetes complications.
Also known as: Foot examination and other screening for diabetes complications, Lipds and renal function
What is the prevalence of glucose intolerance (diabetes and IGT) in patients presenting to an acute medical emergency department?
How many patients not known to have diabetes, are diagnosed with the condition
Time frame: 52 weeks
Diabetes complications, if any, are present
Patients will have foot examination and retinal screening as well tests for renal function
Time frame: 52 weeks
Cardiovascular complications
Presence of coronary artery disease, stroke, peripheral arterial disease
Time frame: 52 weeks
Diabetes control in those with known diabetes
we will assess the control of blood glucose in patients already known to have diabetes
Time frame: 52 weeks
Plan to share: No — All data will kept on trust computer that is password protected. None will be shared with those outside the research team
Ran from Feb 2022 to primary completion in Apr 2025, 38 months.
Of 434 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's 38 months is close to that.
Counting every sponsor, half of 604 studies reached it within 32 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tameside General Hospital